Gilead Sciences awaits a booster

Shareholders of Biopharmaceutical firm, Gilead Sciences (GILD,) might be starting to wonder if it’s time to cash out.

Gilead logo
Source: Bloomberg

The stock has run up 40% since the start of the year, particularly with the US approval of selling its hepatitis C drug, Harvoni.

However, GILD has started to lose some steam over the past month. After hitting an all-time high  of $114.22 just over a month ago, its stock price has since dropped about 8%.

Some of this pressure has come from the growing concerns   that competitive rival drug maker AbbVie could significantly undercut Gilead Sciences in order to win the market share.

We could also see some headwinds with reports last night that Gilead is the target of legal action. Southeastern Pennsylvania Transportation Authority (SEPTA), has filed a lawsuit against the company, accusing it of ‘exorbitant pricing’ over another of its hepatitis C drug, Sovaldi.

Investor’s sentiment could take a further dent on the back of these events, which could see a further pullback in GILD’s stock price.

From a technical perspective, on the daily chart GILD appears to be trading within an upward channel. In the short term its being supported by a floor of $100 and capped by a ceiling of $110.

Fundamentally, there has yet to be any significant material changes in the company, which will be a source of optimism for long-term investors.  The market is generally optimistic on its pipeline of products, which includes clinical trials of at least six potential blockbuster products, such as non-alcoholic steatohepatitis and catering to a range of blood-based disorders.

A pullback towards the support level will present an attractive entry to go long. The stock currently has a 12-month market consensus target price of $126.26 – an upside of over 20%, according to a Bloomberg analyst poll. There are 27 buy calls, 5 hold calls, and none recommending a sell call, based on the survey.

Click to enlarge

IGA, may distribute information/research produced by its respective foreign marketing partners within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IGA Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

See important Research Disclaimer.